Nathalie Baillon-Plot

Antibiotic research and development: business as usual?

Stephan Harbarth, Ursula Theuretzbacher, Judith Hackett et al. · Journal of Antimicrobial Chemotherapy · 2015 · 83 citations · Full text

Pharmacy, Pharmacoeconomics, Antimicrobial Resistance +12

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti et al. · Antimicrobial Resistance and Infection Control · 2019 · 19 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir

Jacqueline Gerhart, Florin Draica, Michael Benigno et al. · The AAPS Journal · 2023 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections

Thitima Kongnakorn, Florian Wagenlehner, Marco Falcone et al. · International Journal of Antimicrobial Agents · 2019 · 17 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in the United States

Amie Scott, Richard Chambers, Maya Reimbaeva et al. · Journal of Medical Economics · 2022 · 14 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +12